Rosemary Harry

Ms. Harry joined the Frazier Healthcare Investment Team in 2001 as an executive in residence working with seed and incubation stage investments.
Since joining Frazier Healthcare, she has worked as the vice president of regulatory affairs, clinical affairs and quality assurance for Calypso Medical Technologies, a Frazier Healthcare portfolio company.
In addition to her role at Calypso, she consults regularly with the Frazier Healthcare Investment team on regulatory issues.
Prior to joining Frazier Healthcare, she was vice president of regulatory and clinical affairs at EKOS Corporation, a development stage drug delivery company, where she created the clinical and regulatory organizations and led the worldwide clinical trials of two innovative Class III intravascular products.
Prior to EKOS, Ms. Harry was director of quality assurance and regulatory affairs for Quinton Instrument Company and manager of clinical research for TPL-Cordis, a Johnson & Johnson Company.
She has a B.S.
degree in biology from St. Mary's College and a master's degree in biomedical engineering from the University of Miami.